Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

Pernille Mensberg; Signe Nyby; Peter Godsk Jørgensen; H Storgaard; Magnus Thorsten Jensen; J Sivertsen; Jens Juul Holst; Bente Kiens; Erik Richter; Filip Krag Knop; Tina Vilsbøll Lauritsen

doi:10.1111/dom.12797

Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

Pernille Mensberg, Signe Nyby, Peter Godsk Jørgensen, H Storgaard, Magnus Thorsten Jensen, J Sivertsen, Jens Juul Holst, Bente Kiens, Erik Richter, Filip Krag Knop, Tina Vilsbøll Lauritsen

17 Citations (Scopus)

131 Downloads (Pure)

Abstract

Aims: To investigate the effects of exercise in combination with a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes. Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training. Results: Glycated haemoglobin (HbA1c) levels dropped by a mean ± standard deviation of 2.0% ± 1.2% (from 8.2% ± 1.4%) in the exercise plus liraglutide group vs 0.3% ± 0.9% (from 8.0% ± 1.2%) in the exercise plus placebo group (P <.001), and body weight was reduced more with liraglutide (−3.4 ± 2.9 kg vs −1.6 ± 2.3 kg; P <.001). Compared with baseline, similar reductions were seen in body fat (exercise plus liraglutide: −2.5% ± 1.4% [P <.001]; exercise plus placebo: −2.2% ± 1.9% [P <.001]) and similar increases were observed in maximum oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 L O₂ /min [P <.001]; exercise plus placebo: 0.4 ± 0.4 L O₂ /min [P =.002]). Greater reductions in fasting plasma glucose (−3.4 ± 2.3 mM vs −0.3 ± 2.6 mM, P <.001) and systolic blood pressure (−5.4 ± 7.4 mm Hg vs −0.6 ± 11.1 mm Hg, P <.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention. Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalized HbA1c levels and caused a robust weight loss when compared with placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.

Original language	English
Journal	Diabetes, Obesity and Metabolism
Volume	19
Issue number	2
Pages (from-to)	172-180
Number of pages	9
ISSN	1462-8902
DOIs	https://doi.org/10.1111/dom.12797
Publication status	Published - 1 Feb 2017

Keywords

Faculty of Science
Exercise
GLP-1
GLP-1 receptor agonist
Glucagon-like peptide-1
Liraglutide
Randomized study
Type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dom.12797Licence: CC BY

Mensberg et al_Diabetes Obesity and Metabolism_2017_Vol 19(2)_172-180Final published version, 632 KBLicence: CC BY

Cite this

Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., Holst, J. J., Kiens, B., Richter, E., Knop, F. K., & Lauritsen, T. V. (2017). Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 19(2), 172-180. https://doi.org/10.1111/dom.12797

Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. / Mensberg, Pernille; Nyby, Signe; Jørgensen, Peter Godsk et al.
In: Diabetes, Obesity and Metabolism, Vol. 19, No. 2, 01.02.2017, p. 172-180.

Research output: Contribution to journal › Journal article › Research › peer-review

Mensberg, P, Nyby, S, Jørgensen, PG, Storgaard, H, Jensen, MT, Sivertsen, J, Holst, JJ , Kiens, B , Richter, E , Knop, FK & Lauritsen, TV 2017, 'Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, vol. 19, no. 2, pp. 172-180. https://doi.org/10.1111/dom.12797

@article{869d73fab88049a6a6acbec4265f46af,

title = "Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes",

abstract = "Aims: To investigate the effects of exercise in combination with a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes. Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training. Results: Glycated haemoglobin (HbA1c) levels dropped by a mean ± standard deviation of 2.0% ± 1.2% (from 8.2% ± 1.4%) in the exercise plus liraglutide group vs 0.3% ± 0.9% (from 8.0% ± 1.2%) in the exercise plus placebo group (P <.001), and body weight was reduced more with liraglutide (−3.4 ± 2.9 kg vs −1.6 ± 2.3 kg; P <.001). Compared with baseline, similar reductions were seen in body fat (exercise plus liraglutide: −2.5% ± 1.4% [P <.001]; exercise plus placebo: −2.2% ± 1.9% [P <.001]) and similar increases were observed in maximum oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 L O2 /min [P <.001]; exercise plus placebo: 0.4 ± 0.4 L O2 /min [P =.002]). Greater reductions in fasting plasma glucose (−3.4 ± 2.3 mM vs −0.3 ± 2.6 mM, P <.001) and systolic blood pressure (−5.4 ± 7.4 mm Hg vs −0.6 ± 11.1 mm Hg, P <.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention. Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalized HbA1c levels and caused a robust weight loss when compared with placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.",

keywords = "Faculty of Science, Exercise, GLP-1, GLP-1 receptor agonist, Glucagon-like peptide-1, Liraglutide, Randomized study, Type 2 diabetes",

author = "Pernille Mensberg and Signe Nyby and J{\o}rgensen, {Peter Godsk} and H Storgaard and Jensen, {Magnus Thorsten} and J Sivertsen and Holst, {Jens Juul} and Bente Kiens and Erik Richter and Knop, {Filip Krag} and Lauritsen, {Tina Vilsb{\o}ll}",

note = "CURIS 2017 NEXS 036",

year = "2017",

month = feb,

day = "1",

doi = "10.1111/dom.12797",

language = "English",

volume = "19",

pages = "172--180",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

AU - Mensberg, Pernille

AU - Nyby, Signe

AU - Jørgensen, Peter Godsk

AU - Storgaard, H

AU - Jensen, Magnus Thorsten

AU - Sivertsen, J

AU - Holst, Jens Juul

AU - Kiens, Bente

AU - Richter, Erik

AU - Knop, Filip Krag

AU - Lauritsen, Tina Vilsbøll

N1 - CURIS 2017 NEXS 036

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Aims: To investigate the effects of exercise in combination with a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes. Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training. Results: Glycated haemoglobin (HbA1c) levels dropped by a mean ± standard deviation of 2.0% ± 1.2% (from 8.2% ± 1.4%) in the exercise plus liraglutide group vs 0.3% ± 0.9% (from 8.0% ± 1.2%) in the exercise plus placebo group (P <.001), and body weight was reduced more with liraglutide (−3.4 ± 2.9 kg vs −1.6 ± 2.3 kg; P <.001). Compared with baseline, similar reductions were seen in body fat (exercise plus liraglutide: −2.5% ± 1.4% [P <.001]; exercise plus placebo: −2.2% ± 1.9% [P <.001]) and similar increases were observed in maximum oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 L O2 /min [P <.001]; exercise plus placebo: 0.4 ± 0.4 L O2 /min [P =.002]). Greater reductions in fasting plasma glucose (−3.4 ± 2.3 mM vs −0.3 ± 2.6 mM, P <.001) and systolic blood pressure (−5.4 ± 7.4 mm Hg vs −0.6 ± 11.1 mm Hg, P <.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention. Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalized HbA1c levels and caused a robust weight loss when compared with placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.

AB - Aims: To investigate the effects of exercise in combination with a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes. Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training. Results: Glycated haemoglobin (HbA1c) levels dropped by a mean ± standard deviation of 2.0% ± 1.2% (from 8.2% ± 1.4%) in the exercise plus liraglutide group vs 0.3% ± 0.9% (from 8.0% ± 1.2%) in the exercise plus placebo group (P <.001), and body weight was reduced more with liraglutide (−3.4 ± 2.9 kg vs −1.6 ± 2.3 kg; P <.001). Compared with baseline, similar reductions were seen in body fat (exercise plus liraglutide: −2.5% ± 1.4% [P <.001]; exercise plus placebo: −2.2% ± 1.9% [P <.001]) and similar increases were observed in maximum oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 L O2 /min [P <.001]; exercise plus placebo: 0.4 ± 0.4 L O2 /min [P =.002]). Greater reductions in fasting plasma glucose (−3.4 ± 2.3 mM vs −0.3 ± 2.6 mM, P <.001) and systolic blood pressure (−5.4 ± 7.4 mm Hg vs −0.6 ± 11.1 mm Hg, P <.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention. Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalized HbA1c levels and caused a robust weight loss when compared with placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.

KW - Faculty of Science

KW - Exercise

KW - GLP-1

KW - GLP-1 receptor agonist

KW - Glucagon-like peptide-1

KW - Liraglutide

KW - Randomized study

KW - Type 2 diabetes

U2 - 10.1111/dom.12797

DO - 10.1111/dom.12797

M3 - Journal article

C2 - 27717126

SN - 1462-8902

VL - 19

SP - 172

EP - 180

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 2

ER -

Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this